Sánchez-Jiménez, Patricia
Elizalde-Horcada, Marcos
Sanz-García, Ancor
Granero-Cremades, Inmaculada
De Toledo, María
Pulido, Paloma
Navas, Marta
Gago-Veiga, Ana Beatriz
Alonso-Guirado, Lola
Alonso-Cerezo, María Concepción
Nava-Cedeño, Desirée
Abad-Santos, Francisco
Torres-Díaz, Cristina Virginia
Ovejero-Benito, María C. http://orcid.org/0000-0003-4082-5165
Funding for this research was provided by:
Instituto de Salud Carlos III (PI2017/02244)
Comunidad de Madrid (CAM.IND2017/BMD-7578)
Article History
Received: 7 October 2022
Accepted: 15 December 2022
First Online: 5 January 2023
Declarations
:
: The protocol and the Informed Consent Form were approved by the Independent Clinical Research Ethics Committee of the Hospital Universitario de La Princesa. The study followed the STROBE guidelines and the Revised Declaration of Helsinki.
: Informed consent was obtained from all individual participants included in the study.
: This manuscript does not contain any individual person’s data in any form (including any individual details, images, or videos).
: F Abad-Santos has been a consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Farmalíder, Ferrer, GlaxoSmithKline, Gilead, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva, and Zambon. AB Gago-Veiga has received honoraria as a consultant and speaker for: AbbVie-Allergan, Chiesi, Exeltis, Novartis, Eli Lilly, and Teva. MC Ovejero-Benito has potential conflicts of interest (honoraria for speaking and research support) with Janssen-Cilag and Leo Pharma. The rest of the authors have no relevant financial or non-financial interests to disclose.